Pharma companies focus on generics market
Dr Reddy's has another acquisition up its sleeve and the deal size could be about $300 million. NDTV has learnt that Dr Reddy's plans to raise $300 million and with the Betapharm acquisition fully financed, another buy-out can be expected in the European region - a move that will help DRL consolidate its generic business.
